European regulators have approved a specialized dietary fibre that triggers the release of glucagon-like peptide 1, or GLP-1, the hormone that reduces appetite and regulates blood sugar. The fibre, called inulin-derived oligofructose, received safety clearance from a European authority and could appear in commercial food products within 12 months.
GLP-1 gained widespread attention through weight-loss drugs like semaglutide, which mimic the hormone's effects. This fibre offers a food-based alternative to pharmaceutical interventions. When consumed, the fibre reaches the colon, where it stimulates specific bacteria and intestinal cells to produce GLP-1 naturally. This approach avoids the need for injections or pills while potentially delivering the hormone's metabolic benefits.
The approval follows years of research into how dietary components influence GLP-1 secretion. Scientists have identified that certain fibres can enhance production of the hormone through the gut's endocrine system, rather than relying on synthetic compounds. This mechanism operates through the gut-brain axis, where intestinal signals regulate appetite and glucose metabolism.
The practical application matters for public health. Obesity and type 2 diabetes affect billions globally, and GLP-1 therapies show promise for both conditions. However, injectable medications remain expensive and require medical supervision. Fortifying common foods with this fibre could democratize access to GLP-1's benefits, particularly in countries with limited healthcare infrastructure.
Researchers have not yet identified which specific foods will receive this additive first. Possibilities include bread, yogurt, and breakfast cereals, where fibre inclusion already occurs naturally. The fibre's taste remains neutral, making it suitable for diverse applications without altering flavour profiles that consumers expect.
Limitations remain. Food-based GLP-1 stimulation likely produces more modest hormone levels than